Cellyan Biotechnology Co., Ltd. has announced a significant corporate action: a 1-for-20 reverse stock split. This decision aims to consolidate its shares to comply with Nasdaq's minimum bid price requirements. The reverse stock split will take effect on October 26, 2026, and is intended to stabilize the company's stock price in a challenging market environment.
The reverse stock split means that every twenty shares of the company's Class A and Class B ordinary shares will be combined into one share. Following this split, the par value of the shares will increase from $0.001 to $0.02. The company assures that this action will not alter any shareholder's percentage interest in the company, except for adjustments related to fractional shares.
Background
Cellyan Biotechnology Co., Ltd. operates in the wholesale-drugs sector, specifically focusing on over-the-counter pharmaceutical cross-border e-commerce supply chain services. The company is listed on Nasdaq under the ticker HKPD and is categorized under the SIC code 5122, which pertains to wholesale drugs, proprietaries, and druggists' sundries. Cellyan has undergone recent changes, including a name change from Hong Kong Pharma Digital Technology Holdings Ltd. earlier this year.
What the Filing Says
The recent filing states, "The Reverse Stock Split is primarily intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market." This highlights the urgency of the company's need to stabilize its stock price to maintain its listing.
Impact
This reverse stock split may affect various stakeholders, including current shareholders and potential investors. By consolidating shares, Cellyan aims to enhance its market perception and attract more institutional investors who may have minimum price thresholds for investment. Additionally, this move may influence other companies in the wholesale-drugs sector, as they observe Cellyan's efforts to navigate the complexities of maintaining a Nasdaq listing.
What's Next
The filing does not say what happens next, but the company will likely monitor its stock performance closely following the reverse split to ensure compliance with Nasdaq's requirements.